AIM: To describe drugs used in the non-hormonal treatment of metastatic prostate cancer.
MATERIAL: Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned.
RESULTS: The metabolic radiotherapy although under-used for this indication, kept a place at the beginning of the disease. Radium-223 chloride seems to have to occupy an important place in the coming years. The chemotherapy, the only recourse until very recently in the castration-resistant prostate cancer, must redefine its place partially. The denosumab provide an interesting alternative to bisphosphonates.
CONCLUSION: The non-hormonal treatment of the metastatic disease of the prostate cancer is changing rapidly with the emergence of new molecules. Urologist must know perfectly these new drugs.
Written by:
Mongiat-Artus P, Brenot-Rossi I, Beuzeboc P, Bruyère F, Karsenty G, Guy L, Bastide C. Are you the author?
Service d'urologie, hôpital Saint-Louis, AP-HP, université Paris 7-Denis-Diderot, 75010 Paris, France.
Reference: Prog Urol. 2013 Nov;23(15):1258-64.
doi: 10.1016/j.purol.2013.08.322
PubMed Abstract
PMID: 24183084
Article in French.
UroToday.com Prostate Cancer Section
